Oncoscience, YM BioSciences, CIMAB cancer news

YM's CIM YM BioSciences Inc. subsidiary, which is partly owned by CIMAB, said it will continue its deal with Oncoscience and will not file for arbitration. In November, YM said it would seek arbitration alleging that Oncoscience's submission of an MAA to EMEA for nimotuzumab did not have the unanimous support of the partners, which is required under their 2006 deal. In December, Oncoscience withdrew its MAA for nimotuzumab. Further terms were not disclosed (see BioCentury, Nov. 24, 2008, & Dec. 8, 2008). ...